Clinical Trials Logo

Clinical Trial Summary

The study evaluates the addition of immunotherapy of PD-1 antibody in neoadjuvant chemoradiotherapy in microsatellite stability-high (MSI-H) locally advanced rectal cancer (LARC). A total of 50 MSI-H LARC patients will receive 2 cycles of PD-1 antibody, followed by capecitabine plus irinotecan radiosensitized neoadjuvant chemoradiotherapy, and another 3 cycles of PD-1 antibody, finally received the total mesorectal excision (TME) and 6 cycles of adjuvant chemotherapy of XELOX. The tumor response grade, adverse effects and long-term prognosis will be analyzed.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04411524
Study type Interventional
Source Fudan University
Contact Zhen Zhang, M.D, PH.D
Phone 18801735029
Email zhen_zhang@fudan.edu.cn
Status Not yet recruiting
Phase Phase 2
Start date July 1, 2020
Completion date December 31, 2022

See also
  Status Clinical Trial Phase
Recruiting NCT05079438 - Dendrobium Huoshanense Suppository in Rectal Cancer Phase 3
Recruiting NCT02964468 - Dose-escalation Trial of Preoperative Radiotherapy and Concurrent Chemotherapy in Locally Advanced Rectal Cancer N/A
Not yet recruiting NCT05507112 - TIME in Immunotherapy Combined With nCRT for Rectal Cancer Phase 2
Not yet recruiting NCT05998122 - Total Neoadjuvant Chemoradiotherapy Plus Anti-PD-1 in Subperitoneal Patients With Locally Advanced Rectal CancerPatients With Locally Advanced Rectal Cancer: A Prospective, Single Arm, Exploratory Study Phase 2
Completed NCT04324567 - Inflammation After Laparoscopic Robot-assisted Surgery for Locally Advanced Rectal Cancer
Recruiting NCT05412082 - SMART TNT for the Conservative Management of Locally Advanced Rectal Cancer Phase 1
Recruiting NCT05980689 - Combination of AK104 and Neoadjuvant Chemoradiotherapy in pMMR/MSS Locally Advanced Rectal Cancer Phase 2
Recruiting NCT02605265 - Trial of Capecitabine With or Without Irinotecan Driven by UGT1A1 Phase 3
Terminated NCT02151019 - Pre-operative 3-DCRT vs IMRT for Locally Advanced Rectal Cancer Phase 1/Phase 2
Recruiting NCT05086627 - Short-course Radiotherapy Followed by Tislelizumab + CapeOX in the Treatment for Locally Advanced Rectal Cancer Phase 2
Not yet recruiting NCT05076305 - PelvEx 4: Advanced Pelvic Malignancy and the Role of the Multi-disciplinary Team Meeting
Recruiting NCT03824899 - UGT1A1 Combined With Pharmacokinetics of SN-38 in CPT-11-based CRT in Patients With Advanced Rectal Cancer N/A
Recruiting NCT05845268 - Total Neoadjuvant Therapy Combined With Tislelizumab for Local Advanced of Middle and Low Rectal Cancer Phase 2
Completed NCT03392584 - Detection and Inflammatory Characterization of Deep Infection After Surgery for Locally Advanced Rectal Cancer With Microdialysis Catheters
Terminated NCT04177602 - Evaluating Trifluridine/Tipiracil Based Chemoradiation in Locally Advanced Rectal Cancer - The Phase I/II TARC Trial Phase 1/Phase 2
Recruiting NCT05646511 - Total Neoadjuvant Therapy of SCRT+CAPOX vs SCRT+CAPOXIRI for Locally Advanced Rectal Cancer (ENSEMBLE) Phase 3
Terminated NCT02290574 - Efficacy of NeoThermo-Radio-chemotherapy for LA Rectal Cancer Before Laparoscopic TME: Prospective Phase II Trial N/A
Recruiting NCT03702985 - Radiation-protection Effect of Amifostine in Locally Advanced Rectal Cancer Phase 2
Active, not recruiting NCT05877352 - Intraoperative Electron Radiotherapy in Rectal Cancer - A Feasibility Trial N/A
Not yet recruiting NCT06375434 - Correlation Between Gut Microbiota and Radiosensitivity of Rectal Cancer